New research moves pramipexole up in the algorithm for treatment resistant depression.

Depression distorts memory. Measurement restores it. 

We interview Steve Hayes, originator of Acceptance and Commitment Therapy, on the personal struggles that inspired the treatment.

In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?

An interview with Steve Hayes, originator of Acceptance and Commitment Therapy (ACT), on how his struggle with panic disorder inspired his work.